Where Apellis Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 10 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. The analysts have an average price target of $102.4 versus the current price of Apellis Pharmaceuticals at $52.46, implying an upside. This current average has increased by 16.55% from the previous average price target of $87.86.
July 18, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Apellis Pharmaceuticals, with an average price target of $102.4, indicating potential upside from the current price of $52.46.
The bullish outlook from analysts is based on their research and understanding of Apellis Pharmaceuticals' business. The average price target of $102.4, which is significantly higher than the current price, indicates that they expect the stock to perform well in the future. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100